Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 341
Filter
2.
Rev Clin Esp (Barc) ; 223(1): 60-61, 2023 01.
Article in English | MEDLINE | ID: mdl-36372381
5.
Rev Clin Esp (Barc) ; 220(2): 115-116, 2020 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-32063263
6.
Rev Clin Esp ; 220(2): 115-116, 2020 Mar.
Article in Spanish | MEDLINE | ID: mdl-34170983
7.
Transpl Infect Dis ; 15(1): E20-4, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23279826

ABSTRACT

We discuss a case of acute disseminated toxoplasmosis in a renal transplant recipient presenting with septic shock. Our literature review of disseminated toxoplasmosis presenting as septic shock reveals a disease process that is rapid and almost uniformly fatal. This unusual presentation warrants a high index of suspicion in transplant recipients with immediate administration of appropriate empiric antimicrobials.


Subject(s)
Kidney Transplantation/adverse effects , Shock, Septic/diagnosis , Toxoplasma/isolation & purification , Toxoplasmosis/diagnosis , Black or African American , Fatal Outcome , Humans , Male , Middle Aged , Shock, Septic/parasitology , Time Factors , Toxoplasmosis/etiology
8.
Clin Microbiol Infect ; 12(2): 170-7, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16441456

ABSTRACT

Candida spp. are an important cause of nosocomial bloodstream infection (nBSI) and are associated with significant morbidity and mortality. An historical cohort study was performed to evaluate the clinical course of 60 randomly selected adult patients with nBSIs caused by Candida spp. Patients with BSI caused by Candida albicans (n = 38) and non-albicans spp. (n = 22) were compared with 80 patients with Staphylococcus aureus BSI by serial systemic inflammatory response syndrome (SIRS) and APACHE II scores. The patients had a mean age of 52 years, the length of hospital stay before BSI averaged 21 days, and 57% of patients required care in an intensive care unit before BSI. The mean APACHE II score was 17 on the day of BSI, and 63% of BSIs were caused by C. albicans. Antifungal therapy within the first 24 h of onset of BSI was appropriate in 52% of patients. Septic shock occurred in 27% of patients, and severe sepsis in an additional 8%. Overall mortality was 42%, and the 7-day mortality rate was 27%. The inflammatory response and clinical course were similar for patients with BSI caused by C. albicans and non-albicans spp. In univariate analysis, progression to septic shock was correlated with high overall mortality, as was an APACHE II score >25 at the onset of BSI. In multivariate analysis, the APACHE II score at the onset of BSI and a systemic inflammatory response independently predicted overall mortality, but the 7-day mortality rate was only predicted independently by the APACHE II score. Clinical course and mortality in patients with Candida BSI were predicted by systemic inflammatory response and APACHE II score, but not by the infecting species.


Subject(s)
Candida/isolation & purification , Candidiasis/physiopathology , Cross Infection/physiopathology , Fungemia/physiopathology , APACHE , Adult , Aged , Aged, 80 and over , Bacteremia/microbiology , Bacteremia/physiopathology , Candidiasis/drug therapy , Candidiasis/microbiology , Candidiasis/mortality , Cross Infection/drug therapy , Cross Infection/microbiology , Cross Infection/mortality , Disease Progression , Female , Fungemia/drug therapy , Fungemia/microbiology , Fungemia/mortality , Humans , Male , Middle Aged , Shock, Septic/microbiology , Shock, Septic/physiopathology , Staphylococcal Infections/microbiology , Staphylococcal Infections/physiopathology , Staphylococcus aureus/isolation & purification , Systemic Inflammatory Response Syndrome/microbiology , Systemic Inflammatory Response Syndrome/physiopathology
9.
Infection ; 33(5-6): 320-6, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16258861

ABSTRACT

BACKGROUND: The aim of this study was to explore characteristics that are associated with bloodstream infections due to specific multiresistant microorganisms (methicillinresitant Staphylococcus aureus, MRSA; vancomycin-resistant enterococci, VRE; third-generation cephalosporin-resistant Enterobacteriaceae) or Candida spp. in hospitalized patients. PATIENTS AND METHODS: All patients who experienced a bloodstream infection with one of the aforementioned pathogens between September 1999 and October 2001 were included into a statistical analysis of independent risk factors. The possible impact of previous antibiotic and antifungal therapies was evaluated. RESULTS: Of the study population, 22% had two or more episodes with different pathogens. In the 314 patients with a single bloodstream infection MRSA was isolated in 189 patients, VRE in 31, Enterobacteriaceae in 13, and Candida spp. in 80 patients. Crude mortality was high in the study population (overall 40%) and varied between 33% (MRSA bacteremia only) and 58% (VRE bacteremia only). Patients who yielded more than one of the pathogens under surveillance had crude mortalities ranging from 41% to 83% (all four pathogens). In this group of high-risk patients, the following factors were independently associated with the individual pathogen: prior chemotherapy (OR 4.88 CI(95) 1.50-15.87) and bronchoscopy (OR 3.17 CI(95) 1.05-9.52) for VRE patients; burns (OR 4.50 CI(95) 0.90-22.73), presence of a tracheostomy (OR 4.22 CI(95) 1.15-15.38) and acute dialysis (OR 3.62 CI(95) 0.99-13.16) for patients with Enterobacteriaceae; and an underlying malignant disease (OR 1.98 CI95 0.99-3.97), performance of a bowel endoscopy (OR 2.80 CI(95) 1.27-6.13) and presence of a central venous catheter (CVC) (OR 12.34 CI(95) 1.63-90.91) for patients with candidemia. CONCLUSION: Patients with bacteremia due to VRE, Enterobacteriaceae or Candida spp. had more severe risk factors associated with the respective pathogen than patients with MRSA bacteremia.


Subject(s)
Bacteremia/microbiology , Cross Infection/epidemiology , Cross Infection/microbiology , Drug Resistance , Fungemia/microbiology , Adult , Aged , Bacteremia/mortality , Candida/drug effects , Candidiasis/epidemiology , Candidiasis/microbiology , Cephalosporin Resistance , Enterobacteriaceae/drug effects , Enterococcus/drug effects , Female , Fungemia/mortality , Gram-Positive Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/microbiology , Humans , Male , Methicillin Resistance , Risk Factors , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Vancomycin Resistance
11.
J Hosp Infect ; 53(2): 103-10, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12586568

ABSTRACT

Methicillin resistance in Staphylococcus aureus has rapidly increased over the last two decades. This increase is paralleled by the emergence of unique multi-resistant MRSA clones. In Brazil, Argentina, Uruguay, Portugal and Czech Republic a specific MRSA clone is widely spread, the so-called Brazilian epidemic clone. Another epidemic clone, the Iberian clone, is disseminated in Spain, Portugal, Belgium, Scotland, Italy, Germany and New York. Thus, a large number of hospital-acquired infections have been caused by specific MRSA clones. Using different molecular techniques for MRSA typing, we verified that two unique epidemic clones are spread over large geographic area in the US. In addition, we showed that a previously described MRSA clone type, the New York clone (I::A:A), is widely spread beyond the New York frontiers.


Subject(s)
Methicillin Resistance/genetics , Staphylococcal Infections/epidemiology , Staphylococcus aureus/drug effects , Cloning, Molecular/methods , Electrophoresis, Gel, Pulsed-Field , Humans , Microbial Sensitivity Tests , Polymorphism, Genetic , Staphylococcal Infections/blood , Staphylococcus aureus/classification , Staphylococcus aureus/isolation & purification , United States/epidemiology
12.
Pediatr Infect Dis J ; 20(12): 1119-24, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11740316

ABSTRACT

BACKGROUND: Candida spp. are increasingly important pathogens in neonatal intensive care units (NICU). Prior colonization is a major risk factor for candidemia, but few studies have focused on risk factors for colonization, particularly in NICU patients. METHODS: A prospective, multicenter cohort study was performed in six NICUs to determine risk factors for Candida colonization. Infant gastrointestinal tracts were cultured on admission and weekly until NICU discharge and health care worker hands were cultured monthly for Candida spp. RESULTS: The prevalence of Candida spp. colonization was 23% (486 of 2157 infants); 299 (14%), 151 (7%) and 74 (3%) were colonized with Candida albicans, Candida parapsilosis and other Candida spp., respectively. Multiple logistic regression analysis adjusting for length of stay, birth weight < or = 1000 g and gestational age < 32 weeks revealed that use of third generation cephalosporins was associated with either C. albicans (155 incident cases) or C. parapsilosis (104 incident cases) colonization. Use of central venous catheters or intravenous lipids were risk factors for C. albicans, whereas delivery by cesarean section was protective. Use of H2 blockers was an independent risk factor for C. parapsilosis. Of 2989 cultures from health care workers' hands, 150 (5%) were positive for C. albicans and 575 (19%) for C. parapsilosis, but carriage rates did not correlate with NICU site-specific rates for infant colonization. CONCLUSIONS: We speculate that NICU patients acquire Candida spp., particularly C. parapsilosis, from the hands of health care workers. H2 blockers, third generation cephalosporins and delayed enteral feedings alter gastrointestinal tract ecology, thereby facilitating colonization.


Subject(s)
Candida/isolation & purification , Candidiasis/transmission , Carrier State/microbiology , Infant, Premature , Intensive Care Units, Neonatal , Candida/growth & development , Candidiasis/epidemiology , Candidiasis/microbiology , Cohort Studies , Digestive System/microbiology , Hand/microbiology , Health Personnel , Humans , Incidence , Infant, Newborn , Prevalence , Prospective Studies , Risk Factors
13.
Acad Med ; 76(12): 1253-6, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11739053

ABSTRACT

PURPOSE: To determine whether the United States Medical Licensing Examination (USMLE) Step 1 score, commonly used in screening residency applicants for interviews, eliminates a greater proportion of African-American applicants from the interview process at an internal medicine residency program. METHOD: A survey of internal medicine residency programs was performed to determine the prevalence of using USMLE Step 1 scores to grant interviews. A cohort of applicants was analyzed by constructing a database of USMLE Step 1 scores from the Electronic Residency Application Service (ERAS) database of applications from U.S., Canadian, and osteopathic medical schools to one residency program in 2000. Each applicant was classified as African American or non-African American. Rejection rates were then calculated for each five-point increment from a hypothetical threshold rejection score of <180 to <215. RESULTS: Responses were received from 259 residency programs (69%), and 92% used the USMLE Step 1 score in deciding which applicants to interview. A cohort of 626 non-African-American and 47 African-American applicants was analyzed. The proportion of applicants below each incremental threshold score was significantly higher for African-American applicants (p <.05 at each level). Depending on the threshold score used, an African-American applicant was three to six times less likely to be offered an interview. CONCLUSIONS: When USMLE Step 1 scores are used to screen applicants for a residency interview, a significantly greater proportion of African-American students will be refused an interview.


Subject(s)
Black or African American/statistics & numerical data , Educational Measurement/statistics & numerical data , Internal Medicine/education , Internal Medicine/statistics & numerical data , Internship and Residency/statistics & numerical data , Interviews as Topic , Licensure, Medical/statistics & numerical data , Prejudice , Cohort Studies , Data Collection , Humans , Odds Ratio , Selection Bias , United States
14.
Clin Infect Dis ; 33(9): 1476-82, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11588692

ABSTRACT

Nosocomial bloodstream infections due to vancomycin-resistant enterococci (VRE) are associated with increased morbidity rates, mortality rates, and hospitalization costs. Gastrointestinal carriage of VRE is an important risk factor for subsequent infections. This 3-arm, phase II, double-blinded, randomized, multicenter, placebo-controlled study evaluated the safety and efficacy of oral ramoplanin (a novel, nonabsorbed glycolipodepsipeptide) versus placebo for suppression of gastrointestinal VRE colonization. Sixty-eight patients who were colonized with VRE were enrolled and received 2 daily doses of ramoplanin (100 mg or 400 mg) or placebo orally for 7 days. The primary end point was the proportion of persons per group from whom VRE were not recovered (VRE-free) on days 7, 14, and 21 after screening. After treatment, VRE-free status was as follows: day 7, none of the 20 patients in the placebo group, and 17 of 21 (P<.001) and 18 of 20 (P<.001) in the 100-mg and 400-mg ramoplanin groups, respectively; on day 14, 2 of 20 patients in the placebo group, and 6 of 21 (P=.134) and 7 of 17 (P=.028), in the 100-mg and 400-mg ramoplanin groups, respectively. By day 21, there were no differences between treatment groups. Adverse events were similar for all treatment groups. Ramoplanin was safe and effective in temporarily suppressing gastrointestinal VRE carriage.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Carrier State/microbiology , Depsipeptides , Digestive System/microbiology , Enterococcus/drug effects , Peptides, Cyclic , Vancomycin Resistance , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Consumer Product Safety , Double-Blind Method , Enterococcus/isolation & purification , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged
15.
Clin Infect Dis ; 33(5): 733-6, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11486296

ABSTRACT

To determine the impact of methicillin resistance on clinical course and outcome, we evaluated nosocomial bloodstream infections (BSIs) due to Staphylococcus aureus that were diagnosed in 82 adult patients at the Medical College of Virginia Hospitals from December 1995 through May 1997. Patients with BSI due to methicillin-resistant S. aureus were compared with patients with BSI due to methicillin-susceptible S. aureus; the groups did not differ with regard to inflammatory response or outcome. Mortality was predicted by systemic inflammatory response and Acute Physiology and Chronic Health Evaluation II score but did not correlate with bacterial resistance to methicillin.


Subject(s)
Bacteremia/complications , Cross Infection/complications , Cross Infection/microbiology , Staphylococcal Infections/complications , Systemic Inflammatory Response Syndrome/microbiology , APACHE , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteremia/mortality , Cohort Studies , Cross Infection/drug therapy , Cross Infection/mortality , Female , Humans , Logistic Models , Male , Methicillin Resistance , Predictive Value of Tests , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcal Infections/mortality , Staphylococcus aureus/isolation & purification
17.
Clin Infect Dis ; 33(2): 177-86, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11418877

ABSTRACT

To assess risk factors for development of candidal blood stream infections (CBSIs), a prospective cohort study was performed at 6 sites that involved all patients admitted to the surgical intensive care unit (SICU) for >48 h over a 2-year period. Among 4276 such patients, 42 CBSIs occurred (9.82 CBSIs per 1000 admissions). The overall incidence was 0.98 CBSIs per 1000 patient days and 1.42 per 1000 SICU days with a central venous catheter in place. In multivariate analysis, factors independently associated with increased risk of CBSI included prior surgery (relative risk [RR], 7.3), acute renal failure (RR, 4.2), receipt of parenteral nutrition (RR, 3.6), and, for patients who had undergone surgery, presence of a triple lumen catheter (RR, 5.4). Receipt of an antifungal agent was associated with decreased risk (RR, 0.3). Prospective clinical studies are needed to identify which antifungal agents are most protective and which high-risk patients will benefit from antifungal prophylaxis.


Subject(s)
Candidiasis/epidemiology , Critical Care , Fungemia/epidemiology , Opportunistic Infections/epidemiology , Adolescent , Adult , Aged , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida/classification , Candida/drug effects , Candida/genetics , Candida/isolation & purification , Candidiasis/blood , Candidiasis/drug therapy , Candidiasis/microbiology , Child , Child, Preschool , Female , Fungemia/blood , Fungemia/drug therapy , Fungemia/microbiology , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Multivariate Analysis , Opportunistic Infections/blood , Opportunistic Infections/drug therapy , Opportunistic Infections/microbiology , Prospective Studies , Risk Factors , United States/epidemiology
18.
Clin Infect Dis ; 32(11): 1538-9, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11340523

ABSTRACT

Patients with fever and neutropenia are at high risk for infection ( approximately 50%) and bacteremia ( approximately 20%). As a result, most are treated with antibacterial prophylaxis until their absolute neutrophil count exceeds 500 cells/mm(3) and their temperature returns to normal. The 1997 guidelines of the Infectious Diseases Society of America suggested 1 of 3 regimens: vancomycin plus ceftazidime, monotherapy with ceftazidime or imipenem (possibly cefepime or meropenem), or dual therapy with an aminoglycoside plus an antipseudomonal beta-lactam.


Subject(s)
Antibiotic Prophylaxis/statistics & numerical data , Antifungal Agents/therapeutic use , Bacteremia/epidemiology , Fever/complications , Mycoses/prevention & control , Neutropenia/complications , Humans
19.
Emerg Infect Dis ; 7(2): 174-7, 2001.
Article in English | MEDLINE | ID: mdl-11294700

ABSTRACT

Nosocomial bloodstream infections are a leading cause of death in the United States. If we assume a nosocomial infection rate of 5%, of which 10% are bloodstream infections, and an attributable mortality rate of 15%, bloodstream infections would represent the eighth leading cause of death in the United States. Because most risk factors for dying after bacteremia or fungemia may not be changeable, prevention efforts must focus on new infection-control technology and techniques.


Subject(s)
Cross Infection/mortality , Sepsis/mortality , Cross Infection/epidemiology , Humans , Sepsis/epidemiology , United States/epidemiology
20.
Clin Infect Dis ; 31(3): 690-7, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11017817

ABSTRACT

We examined the clinical and epidemiological features of nosocomial bloodstream infections (BSIs) caused by Acinetobacter species and observed from 1 March 1995 through 28 February 1998 at 49 United States hospitals (SCOPE National Surveillance Program). Acinetobacter species were found in 24 hospitals (49%) and accounted for 1.5% of all nosocomial BSIs reported. One hundred twenty-nine isolates were identified either as A. baumannii (n=111) or other Acinetobacter species (n=18). Patients with A. baumannii BSI, compared with patients with nosocomial BSI caused by other gram-negative pathogens, were more frequently observed in the intensive care unit (69% vs. 47%, respectively; P<.001; odds ratio [OR] 2.4; 95% confidence interval [CI] 1.6-3.7) and were more frequently receiving mechanical ventilation (58% vs. 30%, respectively; P<.001; OR 3.2; 95% CI 2.1-4.8). Crude mortality in patients with A. baumannii BSI was 32%. Molecular relatedness of strains was studied by use of polymerase chain reaction-based fingerprinting. Clonal spread of a single strain occurred in 5 hospitals. Interhospital spread of epidemic A. baumannii strains was not observed. The most active antimicrobial agents against A. baumannii (90% minimum inhibitory concentration values) were imipenem (1 mg/L; 100% of isolates susceptible), amikacin (8 mg/L; 96%), tobramycin (4 mg/L; 92%), and doxycycline (4 mg/L; 91%). Thirty percent of isolates were resistant to > or =4 classes of antimicrobials and were considered to be multidrug resistant.


Subject(s)
Acinetobacter/isolation & purification , Bacteremia/microbiology , Cross Infection/microbiology , Acinetobacter/drug effects , Acinetobacter/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Bacteremia/blood , Bacteremia/epidemiology , Child , Child, Preschool , Cross Infection/blood , Cross Infection/epidemiology , DNA, Bacterial/genetics , Dose-Response Relationship, Drug , Female , Hospitals , Humans , Infant , Infant, Newborn , Male , Microbial Sensitivity Tests , Middle Aged , Molecular Epidemiology , Polymerase Chain Reaction , Species Specificity , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...